Beyond Dose: Using Pretherapy Biomarkers to Improve Dose Prediction of Outcomes for Radioimmunotherapy of Non-Hodgkin Lymphoma
Open Access
- 1 November 2017
- journal article
- research article
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 32 (9) , 309-319
Abstract
Introduction: Non-Hodgkin Lymphoma patients respond differently to therapy according to inherent biological variations. Pretherapy biomarkers may improve dose-response prediction. Materials and Methods: Hybrid single-photon emission computed tomography (SPECT)/computed tomography (CT) three-dimensional imaging at multiple time points plus follow-up positron emission tomography (PET)/CT or CT at 2 and 6 months post therapy were used to fit tumor response to combined biological effect and cell clearance models from which three biological effect response parameters (radiosensitivity, cold effect sensitivity, and proliferation potential) were determined per patient. A correlation of biological effect parameters and pretherapy biomarker data (ki67, p53, and phospho-histone H3) allowed a dose-based equivalent biological effect (EBE) to be calculated for each patient. Results: Significant correlations were found between biological effect parameters and pretherapy biomarkers. Optimum correlations were found by splitting the patient data according to p53 status. Response correlation of progression free survival (PFS) and EBE were significantly improved compared with PFS and absorbed dose alone. Conclusions: It is possible and desirable to use pretherapy biomarkers to enhance the predictive potential of dose calculations for patient-specific treatment planning.Keywords
This publication has 28 references indexed in Scilit:
- Quantification of Dose Nonuniformities by Voxel-Based Dosimetry in Patients Receiving 90 Y-Ibritumomab-TiuxetanCancer Biotherapy and Radiopharmaceuticals, 2013
- Level of phosphohistone H3 among various types of human cancersBMJ Open, 2012
- Prediction of Therapy Tumor-Absorbed Dose Estimates in I-131 Radioimmunotherapy Using Tracer Data Via a Mixed-Model Fit to Time ActivityCancer Biotherapy and Radiopharmaceuticals, 2012
- Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin’s lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- 131I-Tositumomab Radioimmunotherapy: Initial Tumor Dose–Response Results Using 3-Dimensional Dosimetry Including Radiobiologic ModelingJournal of Nuclear Medicine, 2010
- Methodology to Incorporate Biologically Effective Dose and Equivalent Uniform Dose in Patient-Specific 3-Dimensional Dosimetry for Non-Hodgkin Lymphoma Patients Targeted with 131I-Tositumomab TherapyJournal of Nuclear Medicine, 2010
- Characterization of genetic lesions in apoptosis-regulating and proliferation control genes in diffuse large B-cell non-Hodgkin′s lymphomaJournal of Cancer Research and Therapeutics, 2009
- Malignant Lymphomas Stem from Different B Cell Populations1997
- Pan cycle expression of proliferating cell nuclear antigen in human colorectal cancer and its proliferative correlationsCytometry, 1995
- The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapyBritish Journal of Radiology, 1985